Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, there were no differences between the groups with respect to age, male sex, underlying ESRD cause, medication use, and values of ferritin, TIBC, PTH, calcium, phosphate, C-reactive protein (CRP), TSAT, and Kt/V.Baseline characteristics of patients.Total (n = 142)%HRC < 3.1% (n = 71)%HRC ≥ 3.1% (n = 71)p-valueDemographic dataAge (years)65 (58.0 to 73.0)64.0 (56.0 to 71.5)67.0 (60.5 to 74.0)0.05Male, n (%)80 (56.3)46 (64.8)34 (47.9)0.06Clinical dataHemodialysis duration (months)51.8 (7.5 to 77.4)60.0 (14.7 to 90.1)35.6 (5.4 to 64.1)0.02Underlying end-stage renal disease cause Diabetes, n (%)90 (63.4)48 (67.6)42 (59.2)0.38 Hypertension, n (%)29 (20.4)11 (15.5)18 (25.4)0.21 Glomerulonephritis, n (%)9 (6.3)5 (7.0)4 (5.6)0.73 Polycystic kidney disease, n (%)4 (2.8)1 (1.4)3 (4.2)0.61 Contrast-induced nephropathy, n (%)8 (5.6)6 (8.5)2 (2.8)0.28 Unknown, n (%)2 (1.4)0 (0.0)2 (2.8)0.48Medication use Vitamin D analogs, n (%)69 (48.6)34 (47.9)35 (49.3)0.99 Calcium-based phosphate binder, n (%)62 (43.7)29 (40.8)33 (4.5)0.61 Non-calcium-based phosphate binder, n (%)81 (57)46 (64.8)35 (49.3)0.09 RASB76 (53.5)42 (59.2)34 (47.9)0.24 Darbepoetin alfa, n (%)a126 (88.7)65 (91.5)61 (85.9)0.43 Dose of darbepoetin alfa (μg/week)b26 ± 12.726.3 ± 11.125.6 ± 14.20.743Laboratory parametersHemoglobin (g/dL)10.4 (9.2 to 10.5)10.3 (10.1 to 10.6)10.4 (10.1 -10.6)0.561mo follow-up hemoglobin (g/dL)10.1 (9.6 to 10.4)10.2 (10.0 to 10.6)9.8 (8.7 to 10.2) < 0.001CHr (pg)32.2 ± 2.132.6 ± 1.931.8 ± 2.30.03Ferritin (ng/mL)162.2 (89.3 to 277.8)161.6 (96.9 to 251.7)162.9 (87.2 to 282.5)0.85Iron (ug/dL)62.5 (48.0 to 85.0)69.0 (56.5 to 90.5)57.0 (43.5 to 71.5)0.01TIBC (ug/dL)231.5 (205.0 to 261.0)244.0 (211.5 to 263.5)223.0 (202.0 -254.5)0.09TSAT (%)26.8 (20.7 to 35.1)30.0 (21.5 to 36.5)25.9 (19.3 to 32.5)0.09PTH (pg/mL)244.7 (135.1 to 400.9)253.5 (137.8 to 361.4)244.7 (132.4 to 443.4)0.56Calcium (mg/dL)8.8 (8.3 to 9.1)8.8 (8.4 to 9.2)8.7 (8.2 to 9.0)0.08Phosphate (mg/dL)4.6 (3.7 to 5.5)4.9 (3.8 to 5.7)4.3 (3.5 to 5.2)0.07CRP (mg/L)3.0 (2.0 to 4.0)3.0 (2.0 to 4.0)3.0 (2.0 to 5.0)0.09Kt/V1.5 (1.3 to 1.6)1.4 (1.3 to 1.5)1.5 (1.3 to 1.6)0.37Values are expressed as means ± standard deviations, medians (interquartile ranges), or numbers (percentages).%HRC, percent hypochromic red blood cells; RASB renin: angiotensin: aldosterone system blockade, CHr reticulocyte hemoglobin content, TIBC toral iron-binding capacity, TSAT transferrin saturation, PTH parathyroid hormone, CRP C-reactive protein.aInformation at the time of study enrollment.bInformation between the time of study enrollment and 1 month after study enrollment.Scattered plots of percent hypochromic red cells.

Source: Baseline characteristics of patients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study

Study design awaiting verification · Scientific Reports · 2021

Original publication title

Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study

Youn Kyung Kee; Hee Jung Jeon; Jieun Oh; Dong Ho Shin

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The percentage of hypochromic red blood cells (%HRC) estimates the availability of iron by evaluating the degree of hemoglobinization. We investigated whether %HRC was a predictor of anemia in patients undergoing hemodialysis. We recruited 142 patients undergoing routine hemodialysis between 2017 and 2019. Delta hemoglobin level (ΔHb)1mo-baseline was calculated as the difference between the hemoglobin level at 1 month after study enrollment and that at the time of study enrollment. Development of anemia was defined as hemoglobin level ≤ 15% of baseline.

The median %HRC was 3.1%. There was a significant negative correlation between (ΔHb)1mo: baseline and %HRC (r =  − 0.63, P < 0.001). The incidence of anemia was significantly higher in patients with %HRC > 3.1% than in those with %HRC ≤ 3.1%. In the multivariate logistic regression analysis, %HRC was significantly related to the development of anemia (odds ratio 2.57, 95% confidence interval [CI] 1.72 to 3.85, P < 0.001). The best cutoff value for %HRC to predict the development of anemia was 4.3%, with a sensitivity and specificity of 67.74 (95% CI, 54.7 to 79.1) and 97.50 (95% CI, 91.3 to 99.7), respectively. %HRC is an independent predictor of anemia in patients undergoing hemodialysis. %HRC ≤ 4.3% is an early marker to consider changing the anemia treatment.

Authors’ abstract

The percentage of hypochromic red blood cells (%HRC) estimates the availability of iron by evaluating the degree of hemoglobinization. We investigated whether %HRC was a predictor of anemia in patients undergoing hemodialysis. We recruited 142 patients undergoing routine hemodialysis between 2017 and 2019. Delta hemoglobin level (ΔHb)1mo-baseline was calculated as the difference between the hemoglobin level at 1 month after study enrollment and that at the time of study enrollment. Development of anemia was defined as hemoglobin level ≤ 15% of baseline.

The median %HRC was 3.1%. There was a significant negative correlation between (ΔHb)1mo: baseline and %HRC (r =  − 0.63, P < 0.001). The incidence of anemia was significantly higher in patients with %HRC > 3.1% than in those with %HRC ≤ 3.1%. In the multivariate logistic regression analysis, %HRC was significantly related to the development of anemia (odds ratio 2.57, 95% confidence interval [CI] 1.72 to 3.85, P < 0.001). The best cutoff value for %HRC to predict the development of anemia was 4.3%, with a sensitivity and specificity of 67.74 (95% CI, 54.7 to 79.1) and 97.50 (95% CI, 91.3 to 99.7), respectively. %HRC is an independent predictor of anemia in patients undergoing hemodialysis. %HRC ≤ 4.3% is an early marker to consider changing the anemia treatment.

Publication and source details

Original title: Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study

Youn Kyung Kee; Hee Jung Jeon; Jieun Oh; Dong Ho Shin

Scientific Reports · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T10:44:20.410769+00:00

DOI: 10.1038/s41598-021-03746-2 · PMC8688501